Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings
“These presentations highlight the work underway to leverage our industry-leading capabilities in novel vector development,” said
ARVO 2017 Poster Presentation
Title: Assessment of next-generation AAV variants in gerbil and non-human primate retina following intravitreal injection (Abstract #: 4097 - B0097)
Presenter: Annahita Keravala, Ph.D., Director Novel Vector Technology,
Date/Time:
Session: Drug and Gene Therapy and Delivery
Location: Poster Board #B0097
ASGCT 2017 Poster Presentation
Title: Analysis of gene expression, tissue tropism, and safety of novel AAV variants in mice following intravenous administration
Presenter: Annahita Keravala, Ph.D., Director Novel Vector Technology,
Date/Time:
Session: AAV Vectors I
Location: Exhibit Hall A & B South, #108
About
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Adverum’s plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies and product pipeline, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate in the circumstances. Adverum may not consummate any plans or product or clinical development goals in a timely manner, or at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that Adverum’s resources will not be sufficient for Adverum to conduct or continue planned development programs and planned clinical trials, the risk of a delay in the enrollment of patients in Adverum’s clinical studies or in the manufacturing of products to be used in such clinical studies, the risk that Adverum will not be able to successfully develop or commercialize any of its product candidates, and the risk that Adverum will fail to receive required regulatory approvals. Risks and uncertainties facing Adverum are described more fully in Adverum’s periodic reports filed with the
Contacts for Adverum:Leone Patterson Chief Financial OfficerAdverum Biotechnologies, Inc. 650-665-7222 lpatterson@adverum.comTricia Truehart Vice PresidentThe Trout Group LLC 646-378-2953 ttruehart@troutgroup.com